Comparing Intravenous and Intramuscular Magnesium Sulphate for Preventing Seizure Recurrence in Women With Eclampsia

Launched by NISHTAR MEDICAL UNIVERSITY · May 21, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how the method of giving magnesium sulphate affects the chances of women with eclampsia having repeat seizures. Eclampsia is a serious condition during pregnancy that involves seizures. The researchers want to find out if women who receive magnesium sulphate through a vein (IV) have fewer seizures than those who receive it through a muscle (IM). They will compare two groups of women: one will get magnesium sulphate through an IV, while the other will receive a combination of IV and IM doses.

To participate in this trial, women aged 18 to 45 who are diagnosed with eclampsia in the labor room may be eligible. They will be randomly assigned to one of the two treatment groups and will be monitored in the hospital for any repeat seizures. If a seizure occurs, they will receive an extra dose of magnesium sulphate right away. The treatment will continue for 24 hours after their last seizure or delivery. This study aims to help improve care for women with eclampsia and reduce the risk of future seizures.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Admitted in labor room due to eclampsia (new onset of grand mal seizure activity and/or unexplained coma during pregnancy)
• Exclusion Criteria:
• • Patients with intracranial bleeding (on CT-scan)
• • Already received MgSO4, phenytoin and diazepam before attending the hospital